A step closer to industrial scale manufacture of exosomes - Adaptation of clinical grade neural stem cells from 2D to 3D culture
January 27-31, 2019
Exosomes derived from the clinical grade neural stem cell line CTX (ReNeuron) are the basis of a new class of therapy for the treatment of degenerative disorders. Thus far we have generated CTX-derived exosomes at research scale in 2D planar cultures. Now the cell culture process needs to be scaled up in order to deliver commercially relevant quantities of exosomes that have the correct quality attributes. To meet these demands, CTX cells, which are adherent and habitually grown in a 2D static environment, must be adapted for growth in 3D agitated bioreactor systems.
Please click Additional Files below to see the full abstract.
Nicola Goddard, Dale Moulding, Daniel G. Bracewell, Randolph Corteling, and Ivan Wall, "A step closer to industrial scale manufacture of exosomes - Adaptation of clinical grade neural stem cells from 2D to 3D culture" in "Advancing Manufacture of Cell and Gene Therapies VI", Dolores Baksh, GE Healthcare, USA Rod Rietze, Novartis, USA Ivan Wall, Aston University, United Kingdom Eds, ECI Symposium Series, (2019). http://dc.engconfintl.org/cell_gene_therapies_vi/50